HK2 and arthritic joint disease: An abrogation of the aggressive phenotype of RASF by 2-DG, a non-metabolizable glucose analogue which blocks glycolysis downstream of HK2, has also been described by others [19], and 2-DG has been shown to be effective in reducing the severity of arthritis in a mouse model [55].